Humanized IL-3 Antibodies for Selective Cytokine Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective antibodies with high specificity and affinity for IL-3 that can inhibit its activity in vivo to treat diseases such as rheumatoid arthritis and other autoimmune and inflammatory conditions, while minimizing side effects.
Innovation Solution
Development of humanized antibodies and fragments derived from P8C11, specifically targeting amino acids 41-67 of human IL-3, which exhibit enhanced stability at higher temperatures and broader pH ranges, and do not bind to IL-5 or GM-CSF, retaining full functional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target IL-3, then binding activity is achieved, but specificity and affinity are insufficient and side effects occur
Solution Approach 1:
The patent applies parameter changes by humanizing the antibody sequence (changing from mouse to human immunoglobulin framework) and optimizing binding parameters to achieve high specificity for IL-3 while minimizing cross-reactivity with related cytokines like IL-5 and GM-CSF, thereby reducing side effects
Solution Approach 2:
The patent focuses on creating local quality differentiation by designing antibodies that specifically recognize unique epitopes on IL-3 (amino acids 41-67) without binding to similar structures on other cytokines, achieving selective binding through localized epitope targeting
2Reliability
If antibodies are developed for in vivo activity, then therapeutic efficacy is improved, but stability at higher temperatures and broader pH ranges is reduced
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's physical-chemical properties through humanization and sequence optimization to simultaneously achieve in vivo activity and enhanced stability across broader temperature and pH ranges
3Reliability
If high affinity binding to IL-3 is achieved, then blocking activity is improved, but binding to related cytokines like IL-5 and GM-CSF increases causing off-target effects
Solution Approach 1:
The patent applies local quality by designing antibodies with highly specific epitope recognition focused on unique regions of IL-3 (amino acids 41-67), creating localized binding specificity that prevents cross-reactivity with structurally similar cytokines while maintaining high blocking activity
Solution Approach 2:
The patent uses parameter changes in antibody sequence optimization and humanization to fine-tune binding affinity parameters, achieving high specificity for IL-3 while minimizing affinity for related cytokines through precise immunoglobulin framework and CDR region design
Data Source
AI summary
The present disclosure relates to antibodies and antibody fragment that are specific for IL3, as well as nucleic acids encoding such antibodies and pharmaceutical compositions comprising such antibodies. The antibodies of the present invention are able to block IL-3 activity in target cells and are useful for the prevention and treatment of diseases or malfunctions which are associated with elevated levels of IL3, such as inflammatory diseases, autoimmune diseases, fibrotic diseases, hematologic malignancies and other illnesses.